GlassScriptPhysician profile
Antoinette Green
NPI 1134409576
$2,623.64
in general payments reported to CMS, 2019-2025
18 companies · $645 in 2025
The $645 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $663 · 2022: $361 · 2023: $371 · 2024: $584 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $619.62 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $566.29 | 2021-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $388.70 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $306.81 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.47 | 2021-2024 | Jardiance |
| Abiomed | $103.90 | 2024 | Impella |
| Abbott Laboratories | $94.82 | 2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $75.33 | 2021 | |
| Glaxosmithkline, LLC. | $69.50 | 2021-2023 | Pediarix, Bexsero, Shingrix |
| Xeris Pharmaceuticals, INC. | $43.68 | 2021-2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $33.41 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $26.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $26.23 | 2021 | |
| Becton, Dickinson and Company | $25.07 | 2022 | |
| Astellas Pharma US INC | $24.04 | 2025 | Veozah |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.32 | 2021 | |
| Merck Sharp & Dohme LLC | $22.43 | 2022 | |
| Organon LLC | $19.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoinette Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.